Key Stats for Illumina Stock
- Past-Week Performance: -4.6%
- 52-Week Range: $68.7 to $155.5
- Current Price: $118.9
What Happened?
Illumina (ILMN), the dominant maker of DNA sequencing machines used in cancer diagnostics, genetic disease testing, and drug discovery, posted Q4 2025 adjusted EPS of $1.35, beating the $1.23 consensus estimate by 9.8%, while clinical consumables revenue grew 20% outside China, signaling the turnaround strategy is finally converting into hard numbers at $118.94.
Illumina’s Q4 earnings call confirmed that adjusted EBITDA margin expanded 400 basis points year-over-year to 23.7%, driven by $24 million in lower operating expenses and a 26% increase in operating profit, while full-year 2025 free cash flow reached $931 million and the company returned approximately $740 million to shareholders through buybacks.
The operational engine behind the recovery is the NovaSeq X, Illumina’s flagship high-throughput sequencer that enables clinical labs to run more tests at lower cost per sample: over 100 NovaSeq X instruments placed in Q4 alone, with more than 60% going to clinical customers, pushing the active installed base to 890 globally and driving sequencing output growth of more than 30% year-over-year.
On February 24, Illumina launched TruPath Genome, a whole-genome sequencing workflow priced at $395 per genome that eliminates traditional library preparation and produces results in approximately 10 minutes of hands-on time, directly challenging Roche’s AXELIOS 1 platform at AGBT while offering NovaSeq X customers immediate access without additional hardware investment.
CEO Jacob Thaysen stated on the Q4 2025 earnings call that “the momentum we have built going into 2026 gives me high confidence that the strategy we put in place in 2024 to return to long-term growth is working,” tying directly to 2026 guidance for clinical consumables growth of double-digit to mid-teens and total revenue of $4.5 billion to $4.6 billion.
With the SomaLogic proteomics acquisition closed January 30 adding 1.5 to 2 percentage points of revenue growth in 2026, spatial transcriptomics targeting a H1 2026 launch at a 4x lower cost per insight than existing approaches, and BioInsight pharma collaborations already signed with AstraZeneca, Merck, and Eli Lilly, Illumina is building a data and multiomics platform designed to generate 1% to 2% incremental revenue growth by 2027 on top of the core sequencing recovery.
Wall Street’s Take on ILMN Stock
The 400-basis-point Q4 operating margin expansion that drove a 42% year-over-year EPS beat now confirms the recovery trajectory is structural, not cyclical, directly supporting TIKR’s forward estimates of EBIT margins expanding from 23.1% in 2025 to 24.8% in 2027.
TIKR’s model projects normalized EPS growing from $4.84 in 2025 to $5.84 in 2027, supported by clinical consumables compounding at double-digit to mid-teens rates annually as the 890-unit NovaSeq X installed base, Illumina’s flagship high-throughput sequencer, converts more testing volume to higher-margin recurring consumables revenue.
Wall Street’s conviction is rebuilding but remains split: 8 buys, 1 outperform, 8 holds, 2 underperforms, and 1 sell among 19 analysts, with the mean price target of $136.05 implying 14.4% upside from $118.94, a cautious consensus that has not yet priced the full margin recovery or the multiomics platform optionality.
The spread between the $80.00 low target and the $170.00 high target reflects a genuine bifurcation: bears anchor to Roche’s AXELIOS 1 competitive threat and the 28.4% FCF decline expected in 2026 from SomaLogic integration costs, while bulls underwrite the TruPath Genome and spatial transcriptomics launches driving incremental revenue from 2027 onward.
What Does the Valuation Model Say?
TIKR’s model prices ILMN at $195.12 by December 2030, a 64.1% total return at a 10.9% annualized IRR, anchored to net income margins expanding from 17.4% in 2025 to 22.3% in the mid-case as SomaLogic dilution fades and the multiomics platform reaches commercial scale.
The model’s core assumption is a 5.5% revenue CAGR through 2030, justified by clinical consumables compounding at double-digit rates on top of the 890-instrument NovaSeq X base already contracted and running.
The market is pricing ILMN as a low-growth sequencing hardware company, but a 23.1% EBIT margin already recovered to near-2021 peak levels tells a different story.
The NovaSeq X installed base hitting 890 instruments with 20% clinical consumables growth in Q4 directly justifies TIKR’s $195.12 target: recurring pull-through revenue compounds as labs expand testing volumes.
CEO Jacob Thaysen stated operating margin is “well on that trajectory” toward 26% in 2027, with 130 additional basis points committed in 2026, confirming this is a managed expansion, not a forecast.
The risk is Roche AXELIOS 1 gaining meaningful traction in the whole-genome research segment, which would pressure instrument placements below the 50 to 60 per quarter target and slow the consumables ramp that drives the margin model.
Watch Q1 2026 earnings in late April for clinical consumables growth and NovaSeq X quarterly placements: 50 or more placements with double-digit clinical consumables growth confirms the model is tracking.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ILMN stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
